Table 1

Baseline demographics and characteristics

CharacteristicNatalizumab (n=54)Fingolimod (n=54)
Age, years
 Mean (SD)38.2 (8.8)34.9 (8.7)
 Median (min, max)40 (21, 55)35 (19, 55)
 Sex, n (%) female37 (68.5)38 (70.4)
EDSS score
 Mean (SD)2.5 (1.3)2.6 (1.3)
 Median (min, max)2.0 (0.0, 6.0)2.5 (0.0, 5.5)
 Time since the first MS symptoms, mean (SD), years8.1 (7.7)6.8 (7.0)
 Time since MS diagnosis, mean (SD), years5.0 (5.8)4.5 (5.8)
 Prior MS treatment, n (%) of patients*26 (48.1)28 (51.9)
 Time since most recent relapse, mean (SD), days86.8 (58.8)91.2 (91.4)
 Number of relapses in the past year, mean (SD)1.9 (0.7)1.9 (0.6)
Number of Gd+ lesions
 Mean (SD)2.4 (3.7)2.5 (4.9)
 Median (min, max)1 (0, 14)1 (0, 28)
T2 lesion volume, mL
 Mean (SD)11.9 (9.4)10.9 (10.4)
 Median (min, max)8.5 (0.7, 40.1)7.7 (0.1, 43.2)
T1-non-enhancing lesion volume, mL
 Mean (SD)2.3 (2.4)2.4 (3.4)
 Median (min, max)1.3 (0, 8.6)1.1 (0, 15.3)
  • *Most commonly glatiramer acetate (natalizumab, n=7; fingolimod, n=9) and interferon beta (subcutaneous (SC) interferon beta-1a: natalizumab, n=10; fingolimod, n=6; intramuscular interferon beta-1a: natalizumab, n=4; fingolimod, n=10; SC interferon beta-1b: natalizumab, n=1, fingolimod, n=5; SC interferon beta-1b: natalizumab, n=1, fingolimod, n=2).

  • EDSS, Expanded Disability Status Scale; Gd+, gadolinium enhanced; max, maximum; min, minimum; MS, multiple sclerosis.